6031 - 6040 of 8620 Results
Title
Year
-
RESTRICTEDTitle: Shifting the trajectory of therapeutic development for neurological and psychiatric disordersJournal Name: Science Translational MedicinePublisher: American Association for the Advancement of Science (AAAS)Vol: 15Issue #: 720Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1126/scitranslmed.adg4775Citation Count: 4
-
OPENTitle: The Parkinson's disease gene product DJ-1 modulates miR-221 to promote neuronal survival against oxidative stressJournal Name: Redox BiologyPublisher: Elsevier BVVol: 19Issue #:Start Page: 62End Page: 73Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.redox.2018.07.021Best OA location URL: https://doi.org/10.1016/j.redox.2018.07.021Citation Count: 81
-
OPENTitle: Evolving Applications, Technological Challenges and Future Opportunities in Neuromodulation: Proceedings of the Fifth Annual Deep Brain Stimulation Think TankJournal Name: Frontiers in NeurosciencePublisher: Frontiers Media SAVol: 11Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fnins.2017.00734Best OA location URL: https://www.frontiersin.org/articles/10.3389/fnins.2017.00734/pdfCitation Count: 70
-
OPENTitle: Axonal Tract Reconstruction Using a Tissue-Engineered Nigrostriatal Pathway in a Rat Model of Parkinson’s DiseaseJournal Name: International Journal of Molecular SciencesPublisher: MDPI AGVol: 23Issue #: 22Start Page: 13985End Page: 13985Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3390/ijms232213985Best OA location URL: https://www.mdpi.com/1422-0067/23/22/13985/pdf?version=1668767894Citation Count: 10
-
RESTRICTEDTitle: A Phase 2a study of nilotinib in patients with advanced and early Parkinson’s disease. Study design (P5.068)Journal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 90Issue #: 15_supplementStart Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1212/wnl.90.15_supplement.p5.068Citation Count: 0
-
OPENTitle: Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinson’s disease modelsJournal Name: JCI InsightPublisher: American Society for Clinical InvestigationVol: 6Issue #: 19Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1172/jci.insight.148649Best OA location URL: http://insight.jci.org/articles/view/148649/files/pdfCitation Count: 7
-
RESTRICTEDTitle: The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurementsJournal Name: NeuropharmacologyPublisher: Elsevier BVVol: 105Issue #:Start Page: 651End Page: 660Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neuropharm.2016.01.013Citation Count: 34
-
OPENTitle: The protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variantsJournal Name: Neurobiology of AgingPublisher: Elsevier BVVol: 35Issue #: 1Start Page: 266.e5End Page: 266.e14Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2013.07.013Best OA location URL: https://www.sciencedirect.com/science/article/pii/S0197458013003187Citation Count: 38
-
OPENTitle: Neuroprotection of low dose carbon monoxide in Parkinson’s disease models commensurate with the reduced risk of Parkinson’s among smokersJournal Name: npj Parkinson's DiseasePublisher: Springer Science and Business Media LLCVol: 10Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1038/s41531-024-00763-6Best OA location URL: https://doi.org/10.1038/s41531-024-00763-6Citation Count: 12
-
OPENTitle: Nigral volumetric and microstructural measures in individuals with scans without evidence of dopaminergic deficitJournal Name: Frontiers in NeurosciencePublisher: Frontiers Media SAVol: 16Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fnins.2022.1048945Best OA location URL: https://www.frontiersin.org/articles/10.3389/fnins.2022.1048945/pdfCitation Count: 4